Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy

Nanomedicine

Volumn 9, Issue 5, 2014, Pages 635-647

  Tan, Songwei ^a   Sasada, Tetsuro ^b,c,d   Bershteyn, Anna ^e   Yang, Kunyu ^f   Ioji, Tetsuya ^d   Zhang, Zhiping ^a,b,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Massachusetts Institute of Technology Cambridge   (United States)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

cancer; immunotherapy; lipid coated nanoparticle; melanoma; T cell responses; vaccine antigens

Indexed keywords

HGP100 PEPTIDE; MELANOMA ANTIGEN; P15E PEPTIDE; PEPTIDE VACCINE; POLYGLACTIN; TRP2 PEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CANCER VACCINE; LACTIC ACID; LIPID; NANOCAPSULE; PEPTIDE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CYTOTOXIC T LYMPHOCYTE; DRUG COATING; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOUSE; NANOEMULSION; NANOTECHNOLOGY; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; TUMOR CELL INOCULATION; ANIMAL; C57BL MOUSE; CHEMISTRY; IMMUNOLOGY; MELANOMA; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CELL LINE, TUMOR; LACTIC ACID; LIPIDS; MELANOMA; MICE; MICE, INBRED C57BL; NANOCAPSULES; PEPTIDES; POLYGLYCOLIC ACID; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84901006856     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.67     Document Type: Article

References (53)

1. Melief CJM, Finn OJ. Cancer immunology. Curr. Opin. Immunol. 23(2), 234-236 (2011
2. Speiser DE, Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin. Immunol. 22(3), 144-154 (2010
3. Finn OJ. Molecular origins of cancer-cancer immunology. N. Engl. J. Med. 358(25), 2704-2715 (2008
4. Purcell AW, Mccluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6(5), 404-414 (2007
5. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: Implications for vaccine development. Cell 124(4), 849-863 (2006
6. Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113(11), 1515-1525 (2004
7. Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: Tumor escape from the immune system. Cancer Immunol. Immunother. 60(8), 1161-1171 (2011
8. Garrido F, Algarra I, García-Lora AM. The escape of cancer from T lymphocytes: Immunoselection of MHCclass I loss variants harboring structural-irreversible 'hard' lesions. Cancer Immunol. Immunother 59(10), 1601-1606 (2010
9. Frey AB, Monu N. Signaling defects in anti-Tumor T cells. Immunol. Rev. 222, 192-205 (2008
10. Goldberger O, Volovitz I, Machlenkin A, Vadai E, Tzehoval E, Eisenbach L. Exuberated numbers of tumor-specific T cells result in tumor escape. Cancer Res. 68(9), 3450-3457 (2008
11. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157(3), 1040-1052 (1983
12. Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with adVanced melanoma. N. Engl. J. Med. 364(22), 2119-2127 (2011
13. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004
14. Feyerabend S, SteVanovic S, Gouttefangeas C et al. Novel multi-peptide vaccination in HLA-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69(9), 917-927 (2009
15. Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, Parmiani G. Multipeptide vaccination in cancer patients. Expert Opin. Biol. Ther. 9(8), 1043-1055 (2009
16. Itoh K, Yamada A. Personalized peptide vaccines: A new therapeutic modality for cancer. Cancer Sci. 97(10), 970-976 (2006
17. Valmori D, Dutoit V, Ayyoub M et al. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 3, 15 (2003
18. Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J. Intern. Med. 269(1), 64-73 (2011
19. Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2(1), 37-56 (2010
20. Gilboa E. DC-based cancer vaccines. J. Clin. Invest. 117(5), 1195-1203 (2007
21. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5(4), 296-306 (2005
22. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104(8), 2235-2246 (2004
23. Zhang ZP, Guo YJ, Feng SS. Nanoimmunotherapy: Application of nanotechnology for sustained and targeted delivery of antigens to dendritic cells. Nanomedicine (Lond.) 7(1), 1-4 (2012
24. Gao J, Feng SS, Guo YJ. Nanomedicine against multidrug resistance in cancer treatment. Nanomedicine (Lond.) 7(4), 465-468 (2012
25. Li W, Feng SS, Guo YJ. Block copolymer micelles for nanomedicine. Nanomedicine (Lond.) 7(2), 169-172 (2012
26. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59(6), 478-490 (2007
27. Storni T, Kundig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev. 57(3), 333-355 (2005
28. Shen H, Ackerman AL, Cody V et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117(1), 78-88 (2006
29. Uto T, Wang X, Sato K et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J. Immunol. 178(5), 2979-2986 (2007
30. Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: Developing the next generation of vaccines. Trends Immunol. 27(12), 573-579 (2006
31. Waeckerle-Men Y, Allmen EU, Gander B et al. Encapsulation of proteins and peptides into biodegradable poly(d, l-lactideco-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 24(11), 1847-1857 (2006
32. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(d, l-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22(19), 2406-2412 (2004
33. Zhang ZP, Tongchusak S, Mizukami Y et al. Induction of antitumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 32(14), 3666-3678 (2011
34. Yoshikawa T, Okada N, Oda A et al. Nanoparticles built by self-Assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: A new tumor-vaccine carrier for eliciting effector T cells. Vaccine 26(10), 1303-1313 (2008
35. Hamdy S, Molavi O, Ma ZS et al. Co-delivery of cancerassociated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated antitumor immunity. Vaccine 26(39), 5046-5057 (2008
36. Solbrig CM, Saucier-Sawyer JK, Cody V, Saltzman WM, Hanlon DJ. Polymer nanoparticles for immunotherapy from encapsulated tumor-Associated antigens and whole tumor cells. Mol. Pharm. 4(1), 47-57 (2007
37. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158, 2723-2730 (1997
38. Bershteyn A, Chaparro J, Yau R et al. Polymer-supported lipid shells, onions, and flowers. Soft Matter 4(9), 1787-1791 (2008
39. Zhang JX, Zhu KJ. An improvement of double emulsion technique for preparing bovine serum albumin-loaded PLGA microspheres. J. Microencapsul. 21(7), 11 (2004
40. Sanchez-Perez L, Kottke T, Diaz RM et al. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65(5), 2009-2017 (2005
41. Bai XF, Liu JQ, Joshi PS et al. Different lineages of P1Aexpressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy. Cancer Res. 66(16), 8241-8249 (2006
42. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005
43. Slingluff CL, Petroni GR, Chianese-Bullock KA et al. Immunologic and clinical outcomes of a randomized Phase II trial of two multipeptide vaccines for melanoma in the adjuVant setting. Clin. Cancer Res. 13(21), 6386-6395 (2007
44. Barve M, Bender J, Senzer N et al. Induction of immune responses and clinical efficacy in a Phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J. Clin. Oncol. 26(27), 4418-4425 (2008
45. McCormick AA, Corbo TA, Wykoff-Clary S, Palmer KE, Pogue GP. Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection. Bioconjug. Chem. 17(5), 1330-1338 (2006
46. Mansour M, Pohajdak B, Kast WM et al. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. J. Transl. Med. 5, 20 (2007
47. Yewdell JTW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51-88 (1999
48. Rosenberg SA, Sherry RM, Morton KE et al. Altered CD8+ T-cell responses when immunizing with multiepitope peptide vaccines. J. Immunother. 29(2), 224-231 (2006
49. Chen W, McCluskey J. Immunodominance and immunodomination: Critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv. Cancer Res. 95, 203-247 (2006
50. Sanchez-Perez L, Kottke T, Diaz RM et al. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65(5), 2009-2017 (2005
51. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol. 182(8), 4499-4506 (2009
52. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162-174 (2009
53. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295-307 (2006